Business Standard

Aurobindo's strong European, US prospects keeping analysts bullish

As the pricing pressure in US generics market recedes, the company is also expected to fair well, say analysts, who see growth impetus coming from its recent acquisitions in the US and Europe

Aurobindo Pharma
Premium

Aurobindo Pharma | Photo: Wikipedia

Ujjval Jauhari
The Aurobindo stock is an outlier in the pharma sector, in which many companies have been faced with regulatory, growth, and other issues. 

On Tuesday, it hit a 52-week high, taking the gains to 15 per cent from its February lows. Performance in the US and Europe is a key factor behind the firm figuring in the top pharma picks of analysts. 

The firms has continued to grow well, driven by its large number of filings and niche range of products such as injectables. Thanks to a diversified product basket and limited dependence on any single product, the impact of pricing pressure

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Apr 30 2019 | 7:57 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com